Literature DB >> 30397772

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.

Christine Garcia1, Kari L Ring2.   

Abstract

OPINION STATEMENT: Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.

Entities:  

Keywords:  Cervical cancer; Endometrial cancer; Gynecologic cancer; Immunotherapy; Ovarian cancer; Programmed death ligand-1

Mesh：

Substances：

Year:  2018        PMID： 30397772     DOI： 10.1007/s11864-018-0593-2

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  50 in total

Review 1.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.

Authors:  Megan A Murphy; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

2.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

Authors:  Patrick A Ott; Yung-Jue Bang; Dominique Berton-Rigaud; Elena Elez; Michael J Pishvaian; Hope S Rugo; Igor Puzanov; Janice M Mehnert; Kyaw L Aung; Juanita Lopez; Marion Carrigan; Sanatan Saraf; Mei Chen; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

3.  Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

Authors:  Janice M Mehnert; Anshuman Panda; Hua Zhong; Kim Hirshfield; Sherri Damare; Katherine Lane; Levi Sokol; Mark N Stein; Lorna Rodriguez-Rodriquez; Howard L Kaufman; Siraj Ali; Jeffrey S Ross; Dean C Pavlick; Gyan Bhanot; Eileen P White; Robert S DiPaola; Ann Lovell; Jonathan Cheng; Shridar Ganesan
Journal:  J Clin Invest       Date:  2016-05-09       Impact factor: 14.808

4.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors:  Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal:  J Clin Oncol       Date:  2017-11-02       Impact factor: 44.544

5.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

Review 6.  Role of PD-1 in regulating T-cell immunity.

Authors:  Hyun-Tak Jin; Rafi Ahmed; Taku Okazaki
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

7.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22

10.  Integrated genomic characterization of endometrial carcinoma.

Authors:  Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine
Journal:  Nature       Date:  2013-05-02       Impact factor: 49.962
View more
  6 in total

1.  Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse.

Authors:  Pauline C Xu; Yi Luan; Seok-Yeong Yu; Jing Xu; Donald W Coulter; So-Youn Kim
Journal:  J Endocrinol       Date:  2021-11-24       Impact factor: 4.286

Review 2.  Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.

Authors:  Janelle Sobecki-Rausch; Lisa Barroilhet
Journal:  Curr Treat Options Oncol       Date:  2019-11-21

3.  Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.

Authors:  Lei Zhang; Ying Chen; Fangxuan Li; Lewen Bao; Wenxin Liu
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

4.  Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer.

Authors:  John K Chan; David S Lakomy; Yassmina McDonald; Daniel S Kapp
Journal:  Gynecol Oncol Rep       Date:  2020-05-26

5.  Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.

Authors:  Zhaozhen Wu; Haitao Tao; Sujie Zhang; Xiao Wang; Junxun Ma; Ruixin Li; Zhefeng Liu; Jinliang Wang; Pengfei Cui; Shixue Chen; Huang Di; Ziwei Huang; Xuan Zheng; Yi Hu
Journal:  Cancer Immunol Immunother       Date:  2021-03-19       Impact factor: 6.968

6.  MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.

Authors:  Nan Lu; Jinhui Liu; Chengjian Ji; Yichun Wang; Zhipeng Wu; Shuning Yuan; Yan Xing; Feiyang Diao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.